Gemcitabine 40mg/ml concentrate for solution for infusion - (5ml vial) Malta - English - Medicines Authority

gemcitabine 40mg/ml concentrate for solution for infusion - (5ml vial)

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - gemcitabine hydrochloride - concentrate for solution for infusion - gemcitabine hydrochloride 40 mg - antineoplastic agents

Gemcitabine 40mg/ml concentrate for solution for infusion - (25ml vial) Malta - English - Medicines Authority

gemcitabine 40mg/ml concentrate for solution for infusion - (25ml vial)

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - gemcitabine hydrochloride - concentrate for solution for infusion - gemcitabine hydrochloride 40 mg - antineoplastic agents

Gemcitabine 40mg/ml concentrate for solution for infusion - (50ml vial) Malta - English - Medicines Authority

gemcitabine 40mg/ml concentrate for solution for infusion - (50ml vial)

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - gemcitabine hydrochloride - concentrate for solution for infusion - gemcitabine hydrochloride 40 mg - antineoplastic agents

Gemcitabine Fresenius Kabi 40 mg/ml inf. sol. (conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gemcitabine fresenius kabi 40 mg/ml inf. sol. (conc.) i.v. vial

fresenius kabi sa-nv - gemcitabine hydrochloride - eq. gemcitabine 40 mg/ml - concentrate for solution for infusion - 40 mg/ml - gemcitabine hydrochloride - gemcitabine

Gemcitabine Fresenius Kabi 40 mg/ml inf. sol. (conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gemcitabine fresenius kabi 40 mg/ml inf. sol. (conc.) i.v. vial

fresenius kabi sa-nv - gemcitabine hydrochloride - eq. gemcitabine 40 mg/ml - concentrate for solution for infusion - 40 mg/ml - gemcitabine hydrochloride - gemcitabine

Gemcitabine Fresenius Kabi 40 mg/ml inf. sol. (conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gemcitabine fresenius kabi 40 mg/ml inf. sol. (conc.) i.v. vial

fresenius kabi sa-nv - gemcitabine hydrochloride - eq. gemcitabine 40 mg/ml - concentrate for solution for infusion - 40 mg/ml - gemcitabine hydrochloride - gemcitabine

Gemcitabine 40mg/ml concentrate for solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

gemcitabine 40mg/ml concentrate for solution for infusion

fresenius kabi oncology plc - gemcitabine hydrochloride - concentrate for solution for infusion - 40 milligram(s)/millilitre - pyrimidine analogues; gemcitabine

Gemcitabine 40 mg/ml concentrate for solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

gemcitabine 40 mg/ml concentrate for solution for infusion

fresenius kabi deutschland gmbh - gemcitabine - concentrate for solution for infusion - 40 milligram(s)/millilitre - pyrimidine analogues; gemcitabine

Gemcitabine Kabi gemcitabine (as hydrochloride) 2000 mg/52.6 mL concentrated solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

gemcitabine kabi gemcitabine (as hydrochloride) 2000 mg/52.6 ml concentrated solution for injection vial

fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 2277.2 mg (equivalent: gemcitabine, qty 2000 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic non-small cell lung cancer. gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine kabi, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine kabi, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine kabi, in combinatin with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

Gemcitabine Kabi gemcitabine (as hydrochloride) 1000 mg/26.3 mL concentrated solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

gemcitabine kabi gemcitabine (as hydrochloride) 1000 mg/26.3 ml concentrated solution for injection vial

fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 1138.6 mg (equivalent: gemcitabine, qty 1000 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic non-small cell lung cancer. gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine kabi, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine kabi, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine kabi, in combinatin with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.